Acute Respiratory Distress Syndrome (ARDS) Market Size and Forecast

Acute Respiratory Distress Syndrome (ARDS) Market is projected to expand from US$ 2.87 billion in 2025 to US$ 4.87 billion by 2034, representing a CAGR of 6.04% during 2026–2034. Market growth is being supported by the rising burden of severe respiratory infections, sepsis, pneumonia, and other conditions that can progress to acute respiratory failure. The increasing utilization of advanced critical-care technologies, including lung-protective mechanical ventilation, non-invasive respiratory support, and extracorporeal membrane oxygenation (ECMO), is strengthening treatment capabilities.

What is Acute Respiratory Distress Syndrome (ARDS) and Its Uses & Popularity Worldwide?

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening lung condition in which inflammation and fluid accumulation in the lungs prevent adequate oxygen from reaching the bloodstream. It commonly develops as a complication of serious illnesses or injuries, including pneumonia, sepsis, aspiration, trauma, pancreatitis, and severe infections. ARDS can progress rapidly and is primarily managed in hospitals and intensive care units (ICUs), where continuous monitoring and respiratory support are available. Globally, ARDS is clinically important because it is estimated to occur in approximately 10% of ICU patients worldwide, making it a significant cause of acute respiratory failure.

Treatment focuses on improving oxygenation while addressing the underlying cause. Depending on severity, healthcare professionals may use supplemental oxygen, non-invasive respiratory support, mechanical ventilation, fluid management, prone positioning, and, in selected severe cases, extracorporeal membrane oxygenation (ECMO). Growing investment in intensive-care infrastructure, advanced ventilators, critical-care monitoring, and clinical research is strengthening ARDS management worldwide. Increasing awareness of severe respiratory complications and improvements in early diagnosis are also supporting the development of this important healthcare segment.

Country Acute Respiratory Distress Syndrome (ARDS) Statistics – 2025

1. United States

•  
  • Historical population-based studies have estimated ARDS/acute lung injury incidence in the U.S. at approximately 78.9 cases per 100,000 person-years.
  • A recent nationwide analysis reported 364,924 ARDS-associated deaths from 1999–2023, with a major mortality increase during the COVID-19 period.
  • ARDS remains strongly associated with pneumonia, sepsis and acute respiratory failure.

2. Germany

•  
  • Germany is among the major European markets for ARDS critical care because of its extensive ICU infrastructure and high use of mechanical ventilation.
  • In the multinational LUNG SAFE study, ARDS accounted for 10.4% of ICU admissions globally and 23.4% of patients receiving mechanical ventilation, providing a useful benchmark for German ICU demand.
  • European studies have generally reported ARDS incidence below historical U.S. estimates.

3. China

• Earlier ICU research from Shanghai found that 108 of 5,320 adult ICU admissions (about 2%) met clinical ARDS criteria.
• China’s large population, substantial ICU expansion and continued burden of severe respiratory infections make ARDS an important critical-care issue.
• Respiratory infection surveillance remains particularly important because pneumonia and severe respiratory infections can progress to acute respiratory failure and ARDS.

4. India

• India has a substantial potential ARDS burden because of its very large population and high incidence of severe respiratory infections, sepsis and other ARDS triggers.
• However, nationally representative ARDS incidence data for 2025 are not consistently available, making precise countrywide case estimates difficult.
• Research and ICU-based studies indicate that ARDS represents an important component of severe respiratory failure requiring critical-care management.

5. United Kingdom

• The UK is a major European center for ARDS research and critical-care management.
• European epidemiological studies have reported ARDS occurrence in the range of roughly 7.1%–12.5% of ICU admissions, although estimates vary according to diagnostic criteria and study population.
• The UK has strong adoption of lung-protective ventilation and advanced critical-care practices.

6. France

• France has a well-established critical-care system and extensive use of mechanical ventilation for severe respiratory failure.
• The multinational LUNG SAFE study included French ICUs and found that ARDS represented a substantial proportion of mechanically ventilated patients internationally—23.4% overall.
• Severe ARDS represented approximately 23.4% of identified ARDS cases in the overall study population.

7. Spain

• Spain has historically reported relatively high ARDS incidence compared with several other European countries.
• Published epidemiological estimates have placed ARDS occurrence at approximately 25.5 cases per 100,000 person-years.
• The country therefore represents an important European market for ventilators, ICU monitoring, extracorporeal support and other ARDS-management technologies.

8. Finland

• Finland has reported a substantially lower historical population-based ARDS incidence than the U.S.
• Published European estimates have placed incidence at approximately 10.6 cases per 100,000 person-years.
• Differences between countries reflect variations in population demographics, ICU admission practices, diagnostic recognition and underlying disease burden.

9. Saudi Arabia

• Saudi Arabia does not currently have a widely used national ARDS registry providing a standardized 2025 incidence figure.
• ARDS demand is linked to severe pneumonia, sepsis, trauma and other causes of acute respiratory failure.
• Expansion of ICU capacity, ECMO services and advanced ventilatory technologies under healthcare modernization programs is strengthening the country’s capacity to manage severe ARDS.

10. Australia

• Australia is one of the countries with established population-based ARDS epidemiology and advanced critical-care capabilities.
• Historical research has estimated ARDS incidence at approximately 34 cases per 100,000 person-years.
• Australia has also been an important contributor to international ARDS clinical research and adoption of lung-protective ventilation strategies.

Key Global ARDS Statistics

• ARDS accounted for approximately 10.4% of ICU admissions and 23.4% of mechanically ventilated patients in the large LUNG SAFE international study.
• Among ARDS patients in that study, 30.0% had mild, 46.6% moderate and 23.4% severe ARDS.
• Historical incidence estimates vary considerably by country, from about 10.6 per 100,000 person-years in Finland to 78.9 per 100,000 in the U.S.
• U.S. data show 364,924 ARDS-associated deaths between 1999 and 2023, highlighting the substantial mortality burden of the condition.

Growth Drivers of the Acute Respiratory Distress Syndrome (ARDS) Market

Rising Incidence of Respiratory Failure and Critical Illness

The increasing burden of severe respiratory conditions and critical illnesses is a major driver of the Acute Respiratory Distress Syndrome (ARDS) market. ARDS can develop following pneumonia, sepsis, trauma, aspiration, and other serious medical conditions, creating substantial demand for intensive respiratory support. The World Health Organization estimates that pneumonia caused approximately 2.5 million deaths globally in 2021, highlighting the continuing burden of severe respiratory infections. In intensive-care settings, ARDS remains an important complication among critically ill patients, particularly those with severe infections and systemic inflammation. Aging populations and the increasing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and chronic respiratory conditions can further increase vulnerability to severe illness. Consequently, hospitals are investing in mechanical ventilators, oxygen-delivery systems, monitoring technologies, and other critical-care equipment. Improvements in intensive-care infrastructure, particularly in emerging economies, are also expanding access to advanced respiratory management. The continuing burden of severe respiratory disease therefore supports long-term demand for ARDS diagnosis, monitoring, and treatment solutions.

Advancement in Mechanical Ventilation and Respiratory Support Technologies

Technological advancements in mechanical ventilation and respiratory-support systems are significantly contributing to ARDS market development. Lung-protective ventilation strategies, advanced ventilators, high-flow oxygen therapy, non-invasive ventilation, extracorporeal membrane oxygenation (ECMO), and sophisticated patient-monitoring systems are increasingly incorporated into critical-care settings. The development of modern ventilators with automated controls, real-time monitoring, pressure and volume management, and improved alarm systems enables clinicians to provide more personalized respiratory support. Research has also demonstrated the importance of lung-protective ventilation using lower tidal volumes for patients with ARDS, encouraging hospitals to adopt advanced equipment and standardized treatment protocols. ECMO has additionally gained importance for selected patients with severe respiratory failure when conventional ventilation is insufficient. Improvements in sensors, connectivity, and artificial intelligence are creating opportunities for earlier detection of respiratory deterioration and more precise management. As healthcare providers prioritize improved outcomes and intensive-care efficiency, investments in advanced respiratory-support technologies are expected to remain an important growth factor for the global ARDS market.

Increasing Clinical Research and Development of Novel ARDS Therapies

Growing investment in clinical research and therapeutic development is another important driver of the ARDS market. Historically, ARDS treatment has relied heavily on supportive care because there have been relatively few pharmacological therapies specifically approved for the condition. This unmet medical need is encouraging pharmaceutical and biotechnology companies to investigate new approaches, including anti-inflammatory therapies, immunomodulators, cell-based treatments, and targeted therapies designed to reduce lung injury. Clinical research is also improving understanding of ARDS heterogeneity, allowing researchers to identify patient subgroups that may respond differently to specific interventions. Government agencies, academic institutions, and private organizations continue to support research into improved diagnostic techniques and treatment strategies. The growing use of biomarkers and advanced imaging may also facilitate patient stratification and clinical-trial development. Furthermore, partnerships, acquisitions, and funding programs can accelerate the movement of promising therapies from early-stage research toward clinical testing. As the global medical community seeks treatments capable of reducing mortality, shortening intensive-care stays, and improving recovery, continued R&D activity is expected to create new opportunities in the ARDS market.

Challenges of the Acute Respiratory Distress Syndrome (ARDS) Market

High Mortality and Limited Disease-Specific Treatment Options

The absence of widely available disease-modifying therapies specifically approved for ARDS remains a major challenge for market development. ARDS is a complex syndrome rather than a single disease, and patients can develop the condition from different underlying causes, including pneumonia, sepsis, aspiration, trauma, and other critical illnesses. This biological diversity makes it difficult to develop therapies that demonstrate consistent benefits across all patient populations. Mortality also remains substantial, particularly among patients with severe disease and multiple organ failure. Current management primarily focuses on supportive approaches such as lung-protective mechanical ventilation, appropriate fluid management, prone positioning in selected patients, and treatment of the underlying cause. Although these approaches have improved outcomes, they do not directly eliminate the underlying lung injury. Pharmaceutical companies therefore face considerable challenges in identifying effective drug targets and designing clinical trials with clearly defined patient populations. Failure of investigational therapies in clinical development can increase research costs and discourage investment. Consequently, the limited availability of disease-specific pharmacological treatments continues to restrict the expansion of the therapeutic ARDS market.

High Cost of Intensive-Care Treatment and Unequal Healthcare Access

The high cost and complexity of ARDS management represent another significant challenge, particularly in developing and low-resource healthcare systems. Severe ARDS often requires intensive-care hospitalization, mechanical ventilation, continuous monitoring, specialized nursing, and multidisciplinary medical expertise. Advanced interventions such as ECMO can require highly specialized equipment and trained personnel, substantially increasing treatment expenses. In addition, prolonged ICU stays can place considerable financial pressure on hospitals, patients, and healthcare systems. Access to advanced respiratory-support technologies also varies considerably between high-income and low- and middle-income countries. Hospitals in resource-constrained regions may face shortages of ventilators, ICU beds, trained respiratory specialists, and critical-care infrastructure. These limitations can delay diagnosis and reduce access to advanced treatment options. Even in developed healthcare systems, rising equipment, staffing, and hospitalization costs can create budgetary pressures. Expanding critical-care infrastructure, improving reimbursement mechanisms, increasing healthcare workforce capacity, and developing more affordable technologies will therefore be important for improving access and supporting broader ARDS market growth.

Acute Respiratory Distress Syndrome (ARDS) Treatment Product Launches / Developments Worldwide

• 1. GOHIBIC® (vilobelimab) – European Union, 2025: InflaRx received European Commission marketing authorization in January 2025 for GOHIBIC to treat adults with SARS-CoV-2-induced ARDS who receive systemic corticosteroids and invasive mechanical ventilation, with or without ECMO. It became the first treatment authorized in the EU specifically for SARS-CoV-2-induced ARDS.
• 2. MultiStem® (HLCM051) – Japan/Global, 2024–2026: Healios advanced its allogeneic cell therapy MultiStem for pneumonia-associated ARDS, initiating a Phase 3 program in Japan and progressing toward the global REVIVE-ARDS Phase 3 study. The therapy has received FDA Fast Track and RMAT designations for ARDS.
• 3. Plerixafor – Europe, 2024: The European Medicines Agency granted orphan designation to plerixafor for the treatment of ARDS in February 2024. The designation provides regulatory and scientific support for further development, although it does not represent marketing authorization or a commercial launch.
• 4. Paridiprubart (EB05) – United States/Canada, 2024–2025: Edesa Biotech continued development of EB05, an experimental host-directed therapy for ARDS. In 2025, the company reported positive Phase 3 results, representing an important advancement toward a potential disease-specific ARDS therapy.
• 5. GOHIBIC® BARDA Development Program – United States, 2024: GOHIBIC was selected for a BARDA-sponsored clinical program evaluating host-directed therapies for ARDS. The initiative expanded investigation of vilobelimab beyond its existing COVID-19-related development pathway.
• 6. EB05 BARDA-Supported Program – United States, 2024–2025: Edesa’s paridiprubart was included in a U.S. government-supported ARDS development program. The Canadian government also committed up to CAD$23 million toward development activities, including Phase 3 clinical research and potential regulatory preparation.
• 7. Aviptadil ARDS Treatment Program – Europe, 2023–2024: Aviptadil continued to be investigated as an adjunct treatment for severe respiratory failure and ARDS. Clinical research published in 2024 evaluated its potential effects on oxygenation and survival in ARDS patients, although it remained investigational rather than an approved ARDS product.
• 8. Modular Prone-Positioning Tools – China, 2024: Researchers introduced and clinically evaluated innovative modular prone-positioning tools for patients with COVID-19-associated ARDS. The prospective randomized study included 76 patients, assessing comfort, adverse events, and treatment-related outcomes.
• 9. Smart ICU ARDS Management Platform – China, 2024–2025: A smart ICU cloud platform for ARDS management was implemented at a Chinese hospital in 2024. An analysis involving 145 ARDS patients found that patients managed using the smart system experienced significantly reduced invasive mechanical-ventilation time.
• 10. VQ Biomedical Lung-Injury Treatment Device – United States, 2025: Duke-affiliated startup VQ Biomedical secured US$5 million in March 2025 to advance a less-invasive catheter-based technology intended to treat severe lung injuries, particularly ARDS. The funding was aimed at prototype development and preparation for clinical trials.

Growing Adoption of Advanced Respiratory Support and Critical-Care Therapies

ARDS treatment market is driven primarily by the increasing use of advanced respiratory-support technologies and evidence-based intensive-care therapies. ARDS affects approximately 10% of ICU admissions and about 23% of patients requiring mechanical ventilation, making it an important source of demand for ventilators and critical-care equipment. Treatment commonly involves lung-protective mechanical ventilation, appropriate PEEP, prone positioning, fluid management, and, in selected severe cases, extracorporeal membrane oxygenation (ECMO). Modern ventilators increasingly provide precise control of tidal volume, airway pressure, oxygen concentration, and respiratory rate, supporting individualized treatment. The high mortality associated with ARDS also encourages hospitals to invest in technologies capable of improving outcomes. A large international study reported hospital mortality of 34.9% for mild, 40.3% for moderate, and 46.1% for severe ARDS. Consequently, rising critical-care capacity, improved ventilator technology, and increasing awareness of lung-protective treatment strategies are expected to sustain demand for ARDS treatment products and services.

Increasing Demand for Early and Accurate Respiratory Assessment

ARDS diagnosis market is expanding as healthcare providers increasingly emphasize early identification and severity assessment of acute respiratory failure. Diagnosis generally relies on clinical evaluation, oxygenation measurements, chest imaging, and assessment of the underlying cause, with arterial blood gas testing and pulse oximetry playing important roles. ARDS can be difficult to recognize because it frequently occurs alongside conditions such as pneumonia, sepsis, trauma, and aspiration. In a major international ICU study, ARDS accounted for 10.4% of ICU admissions, while clinical recognition ranged from 51.3% in mild cases to 78.5% in severe cases, demonstrating the continuing diagnostic challenge. Advanced imaging, continuous oxygen monitoring, blood-gas analyzers, and digital clinical decision-support systems are therefore becoming increasingly important. Earlier identification can help clinicians implement lung-protective ventilation and other interventions sooner. The development of biomarkers and artificial-intelligence-assisted diagnostic technologies may further improve patient stratification. As hospitals seek faster diagnosis and more precise severity classification, demand for respiratory monitoring and diagnostic technologies is expected to increase.

Hospitals Remain the Primary Treatment and Management Setting

Hospitals represent the dominant end-user environment for ARDS diagnosis, treatment, monitoring, and intensive respiratory support because severe cases generally require specialized critical-care facilities. ARDS patients may need mechanical ventilation, continuous oxygen monitoring, blood-gas analysis, prone positioning, sedation, and treatment of the underlying condition. The substantial resource requirements of ARDS create significant demand for ICU beds, ventilators, monitoring systems, respiratory-care equipment, and specialized healthcare professionals. International evidence shows that ARDS represented 23.4% of patients requiring mechanical ventilation in the LUNG SAFE study, demonstrating its considerable impact on hospital critical-care resources. In another analysis, ARDS was associated with approximately 39.4% pooled mortality across studies published from 2009–2019. Hospitals are consequently increasing their focus on advanced respiratory-care capabilities and multidisciplinary critical-care teams. Expansion of ICUs in emerging economies, modernization of hospital infrastructure, and greater adoption of sophisticated ventilators and patient-monitoring technologies are expected to support the hospital segment. The complexity of severe ARDS ensures that hospitals will remain the central treatment setting.

Expansion of Specialized Respiratory and Pulmonary Care Services

Specialty clinics are developing an increasingly important role in respiratory assessment, follow-up, rehabilitation, and management of patients recovering from severe lung injury. Although acute severe ARDS is primarily managed in hospitals and ICUs, specialty pulmonary and respiratory clinics can support patients after discharge by evaluating persistent respiratory symptoms, lung-function impairment, exercise capacity, and quality-of-life changes. ARDS survivors may experience prolonged physical and pulmonary consequences, creating demand for specialized follow-up services. The high severity of the condition reinforces the need for multidisciplinary care; international ICU data reported hospital mortality ranging from 34.9% in mild ARDS to 46.1% in severe ARDS. Specialty clinics can also assist with pulmonary rehabilitation, oxygen assessment, medication management, and monitoring for long-term complications. Growing awareness of post-ICU care is encouraging healthcare systems to establish structured respiratory follow-up pathways. In addition, improvements in diagnostic monitoring and telemedicine can enable specialists to track patients remotely. As survival improves and more patients require post-acute respiratory care, specialty clinics are expected to become an increasingly relevant component of the broader ARDS care market.

Rising Need for Post-Discharge Respiratory Monitoring and Rehabilitation

The ARDS home healthcare market is emerging as healthcare systems increasingly shift appropriate post-acute care from hospitals to patients’ homes. Acute severe ARDS generally requires hospitalization, so home healthcare is more relevant to the recovery and rehabilitation phase rather than initial emergency treatment. Patients recovering from severe respiratory failure may require supplemental oxygen, respiratory monitoring, physiotherapy, nutritional support, medication management, and follow-up consultations. The need for such services is supported by the substantial clinical burden of ARDS: a meta-analysis covering 56,081 critically ill patients found mortality was significantly higher among patients with ARDS than among comparable critically ill patients without ARDS. Home-based monitoring can help healthcare professionals track oxygen saturation, respiratory symptoms, functional recovery, and other indicators while potentially reducing unnecessary hospital visits. Remote consultations and connected medical devices can further support post-discharge management. As hospitals face pressure to shorten stays and reduce healthcare costs, home-based respiratory rehabilitation and monitoring are becoming more attractive. Consequently, increasing survival, aging populations, and wider adoption of remote-care technologies are expected to create opportunities for the ARDS home healthcare segment.

Advanced Critical-Care Infrastructure Supporting USA Market Expansion

The United States remains one of the leading markets for Acute Respiratory Distress Syndrome (ARDS), supported by extensive ICU capacity, advanced respiratory-care infrastructure, and strong investment in medical innovation. ARDS is a major critical-care condition; international ICU research has found that it affects approximately 10.4% of ICU admissions and 23.4% of patients receiving mechanical ventilation. The U.S. healthcare system has broad access to sophisticated ventilators, ECMO systems, continuous patient-monitoring technologies, and advanced diagnostic equipment. The presence of major academic medical centers also supports clinical research into novel ARDS therapies, biomarkers, and regenerative approaches. Government-backed programs, including support for ARDS therapeutic development, further encourage pharmaceutical and biotechnology companies to advance clinical pipelines. High rates of conditions associated with ARDS, including pneumonia, sepsis, aspiration, and severe trauma, maintain demand for intensive respiratory care. In addition, established reimbursement mechanisms and specialist expertise facilitate adoption of advanced treatment protocols. Growing use of lung-protective ventilation, prone positioning, and extracorporeal support is expected to continue strengthening the U.S. ARDS market.

Strong ICU Capabilities and Emphasis on Evidence-Based Treatment in United Kingdom

Germany represents an important European market for ARDS treatment because of its highly developed healthcare infrastructure, sophisticated intensive-care facilities, and strong emphasis on clinical standards. ARDS is particularly relevant in critical-care settings, with international research identifying the syndrome in a substantial proportion of mechanically ventilated patients. German hospitals increasingly employ lung-protective mechanical ventilation, advanced oxygenation monitoring, prone positioning, and ECMO for appropriately selected patients with severe respiratory failure. The country’s comprehensive healthcare financing system supports access to advanced hospital-based treatment and critical-care equipment. Germany also has a strong medical technology and pharmaceutical industry, facilitating access to modern ventilators, patient-monitoring systems, diagnostic equipment, and investigational therapies. An aging population and the continuing burden of pneumonia, sepsis, cardiovascular disease, and other serious illnesses contribute to the potential ARDS patient pool. Furthermore, German universities and research institutions participate in international clinical studies investigating anti-inflammatory, immunomodulatory, and regenerative approaches. Continued investment in critical-care modernization and clinical research is expected to sustain demand for advanced ARDS management solutions.

Expanding Critical-Care Infrastructure and Respiratory Disease Burden in China

China’s ARDS market is expanding as the country’s healthcare system invests heavily in intensive-care infrastructure, respiratory medicine, and advanced hospital technologies. Severe pneumonia, respiratory infections, sepsis, and other critical illnesses create substantial demand for mechanical ventilation and intensive respiratory monitoring. China’s large population also provides a significant patient base for critical-care services and clinical research. Hospitals in major urban centers are increasingly equipped with advanced ventilators, ECMO systems, blood-gas analyzers, and digital monitoring technologies, while healthcare modernization is gradually extending sophisticated critical-care capabilities to regional facilities. Domestic medical-device manufacturers are strengthening their presence in ventilators and respiratory-support equipment, potentially improving affordability and supply availability. China is also becoming increasingly active in research involving innovative ARDS therapies, including anti-inflammatory approaches and cell-based treatments. The development of smart hospitals and digital healthcare platforms is creating additional opportunities for connected respiratory monitoring and clinical decision support. As ICU capacity continues to expand and clinicians gain greater familiarity with evidence-based ARDS protocols, demand for diagnosis, treatment, monitoring, and critical-care technologies is expected to increase.

Vision 2030 Healthcare Transformation Driving Advanced ARDS Care in Saudi Arabia

Saudi Arabia’s ARDS market is developing steadily as healthcare modernization under Vision 2030 drives investment in hospitals, intensive-care units, and advanced medical technologies. Severe respiratory infections, pneumonia, trauma, sepsis, and chronic diseases can increase the need for high-acuity respiratory support, creating demand for ARDS diagnosis and treatment capabilities. Saudi hospitals are increasingly adopting modern mechanical ventilators, advanced patient-monitoring systems, and ECMO capabilities for appropriately selected patients with severe respiratory failure. Government investment in healthcare infrastructure is also supporting the development of specialized critical-care centers and improved emergency services. International clinical protocols and evidence-based approaches, including lung-protective ventilation and prone positioning, are becoming increasingly integrated into critical-care practice. The private healthcare sector is contributing further through investments in advanced medical equipment and specialized services. Training programs for physicians, nurses, respiratory therapists, and critical-care specialists are also improving the country’s ability to manage complex respiratory conditions. With continuing healthcare infrastructure development, greater adoption of advanced technologies, and increasing emphasis on specialized care, Saudi Arabia is expected to remain an important emerging ARDS market in the Middle East.

Recent Developments in Acute Respiratory Distress Syndrome Market

• In May 2025, clinical researchers released findings showing that acetaminophen may help reduce the likelihood of developing acute respiratory distress syndrome and organ damage among sepsis patients, indicating its potential as a supportive therapeutic option.
• In April 2025, BioAegis Therapeutics reported that the FDA granted Fast Track designation to its lead candidate, recombinant human plasma gelsolin, for the treatment of acute respiratory distress syndrome, expediting its clinical development and regulatory review.
• In February 2025, CytoVance Biologics received accelerated FDA approval for Avelumab-X, a new monoclonal antibody designed to treat sepsis-induced acute respiratory distress syndrome, following encouraging outcomes from its Phase II clinical trial.

Acute Respiratory Distress Syndrome Market Segments

Type

• Diagnosis
• Treatment

End User

• Hospitals
• Specialty clinics
• Home healthcare
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

All the Key players have been covered from 5 Viewpoints:

• Overview
• Key Person
• Product Analysis
• Recent Development
• Revenue

Key Players Analysis

• Ajanta Pharma Limited
• Akorn Operating Company LLC
• Alembic Pharmaceutical Ltd.
• Cipla Inc.
• Indoco Remedies Ltd.
• Johnson & Johnson
• Novartis AG
• Ocular Therapeutix, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Report Details: